BMY responded to the FDA’s Belatacept CRL, but the FDA told BMY a decision on the BLA is on hold until BMY brings manufacturing at its Puerto Rico plant into compliance. This will delay a decision on the Belatacept BLA until at least 2Q11. (Source: BMY’s 3Q10 CC)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.